# Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction

Study · id `cardio:ct-nct04369534` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04369534](<https://clinicaltrials.gov/study/NCT04369534>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04369534

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT04369534. Randomized; no masking; primary purpose treatment. Start 2015-12-01 (actual); primary completion 2019-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT04369534, source copy `cardio:ctgov-nct04369534-2020-04-30`, retrieved 2026-10-26)
- Started: 2015-12-01 (actual) (ClinicalTrials.gov record NCT04369534, source copy `cardio:ctgov-nct04369534-2020-04-30`, retrieved 2026-10-26)
- Primary completion: 2019-11-30 (actual) (ClinicalTrials.gov record NCT04369534, source copy `cardio:ctgov-nct04369534-2020-04-30`, retrieved 2026-10-26)
- Completion: 2019-12-01 (actual) (ClinicalTrials.gov record NCT04369534, source copy `cardio:ctgov-nct04369534-2020-04-30`, retrieved 2026-10-26)
- Countries: Croatia (ClinicalTrials.gov record NCT04369534, source copy `cardio:ctgov-nct04369534-2020-04-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04369534-2020-04-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
- Acronym: SPARELIFE
- Condition: Acute Coronary Syndrome
- Condition: STEMI
- Condition: NSTEMI - Non-ST Segment Elevation MI
- Condition: PLATELET AGGREGATION
- Condition: INDIVIDUALIZED THERAPY
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Ticagrelor
- Lead sponsor: University of Zagreb
- Lead sponsor class: OTHER
- Collaborator: Croatian Science Foundation
- Collaborator class: OTHER\_GOV
- Collaborator: Clinical Hospital Centre Zagreb
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: University of Zagreb (`cardio:org-university-of-zagreb`)

## Provenance

Content hash: a950f7ac84735311e4ee6c4337111df27326d836113df40d98b483d1745edbf3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
